WO2000007541A3 - Verwendung von xanthinderivaten zur behandlung von erektionsstörungen - Google Patents

Verwendung von xanthinderivaten zur behandlung von erektionsstörungen Download PDF

Info

Publication number
WO2000007541A3
WO2000007541A3 PCT/EP1999/005108 EP9905108W WO0007541A3 WO 2000007541 A3 WO2000007541 A3 WO 2000007541A3 EP 9905108 W EP9905108 W EP 9905108W WO 0007541 A3 WO0007541 A3 WO 0007541A3
Authority
WO
WIPO (PCT)
Prior art keywords
treating erectile
xanthine derivatives
erectile disorder
formula
enantiomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1999/005108
Other languages
English (en)
French (fr)
Other versions
WO2000007541A2 (de
Inventor
Gabriele Wiemer
Karl Rudolphi
Dieter Ruppert
Wolfgang Losert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Aventis Pharma Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1998134604 external-priority patent/DE19834604A1/de
Priority claimed from DE1998141051 external-priority patent/DE19841051A1/de
Priority claimed from DE1998142906 external-priority patent/DE19842906A1/de
Priority claimed from DE1999119828 external-priority patent/DE19919828A1/de
Application filed by Aventis Pharma Deutschland GmbH filed Critical Aventis Pharma Deutschland GmbH
Priority to AU50384/99A priority Critical patent/AU5038499A/en
Publication of WO2000007541A2 publication Critical patent/WO2000007541A2/de
Publication of WO2000007541A3 publication Critical patent/WO2000007541A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Verbindungen der Formel (I) (Propentofylline) oder der Formel (II), wobei die Verbindung der Formel (II) als Razemat oder als S- oder R-Enantiomer vorliegt, eignen sich zur Herstellung eines Arzneimittels zur Behandlung von Erektionsstörungen und zur nicht therapeutischen Anwendung.
PCT/EP1999/005108 1998-07-31 1999-07-17 Verwendung von xanthinderivaten zur behandlung von erektionsstörungen Ceased WO2000007541A2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU50384/99A AU5038499A (en) 1998-07-31 1999-07-17 Use of xanthine derivatives for treating erectile disorder

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
DE1998134604 DE19834604A1 (de) 1998-07-31 1998-07-31 Verwendung von Xanthinderivaten zur Behandlung von Erektionsstörungen
DE19834604.2 1998-07-31
DE1998141051 DE19841051A1 (de) 1998-09-09 1998-09-09 Verwendung von Xanthinderivaten zur Behandlung von Erektionsstörungen
DE19841051.4 1998-09-09
DE1998142906 DE19842906A1 (de) 1998-09-18 1998-09-18 Verfahren von Xanthinderivaten zur Behandlung von Erektionsstörungen
DE19842906.1 1998-09-18
DE1999119828 DE19919828A1 (de) 1999-04-30 1999-04-30 Verwendung von Xanthinderivaten zur Behandlung von Erektionsstörungen
DE19919828.4 1999-04-30

Publications (2)

Publication Number Publication Date
WO2000007541A2 WO2000007541A2 (de) 2000-02-17
WO2000007541A3 true WO2000007541A3 (de) 2000-05-04

Family

ID=27438843

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/005108 Ceased WO2000007541A2 (de) 1998-07-31 1999-07-17 Verwendung von xanthinderivaten zur behandlung von erektionsstörungen

Country Status (2)

Country Link
AU (1) AU5038499A (de)
WO (1) WO2000007541A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10130504B4 (de) 2001-06-25 2005-02-03 Nutrinova Nutrition Specialties & Food Ingredients Gmbh Xanthin- und Phenazon-Acesulfam-H-Komplexe mit verbessertem Geschmack, Verfahren zu ihrer Herstellung und ihre Verwendung
CN107001371B (zh) 2014-10-09 2019-07-05 广东众生睿创生物科技有限公司 羟基嘌呤类化合物及其应用
CN111233863B (zh) * 2014-10-09 2022-10-25 广东众生睿创生物科技有限公司 羟基嘌呤类化合物及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0344324A (ja) * 1989-07-13 1991-02-26 Kazuoki Tsuchiya 性機能賦活剤
JPH09169665A (ja) * 1995-12-21 1997-06-30 Kenichi Miyamoto 骨粗鬆症治療剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0344324A (ja) * 1989-07-13 1991-02-26 Kazuoki Tsuchiya 性機能賦活剤
JPH09169665A (ja) * 1995-12-21 1997-06-30 Kenichi Miyamoto 骨粗鬆症治療剤

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BORGLAND, STEPHANIE L. ET AL: "Effects of propentofylline on adenosine receptor activity in Chinese hamster ovary cell lines transfected with human A1, A2A, or A2B receptors and a luciferase reporter gene", CAN. J. PHYSIOL. PHARMACOL. (1998), 76(12), 1132-1138, XP000836562 *
JOHNSON, MICHAEL P. ET AL: "Temporal-dependent neuroprotection with propentofylline (HWA 285) in a temporary focal ischemia model", EUR. J. PHARMACOL. (1998), 346(2/3), 151-157, XP000863577 *
NOBLE, STUART ET AL: "Propentofylline", CNS DRUGS (1997), 8(3), 257-264, XP000863567 *
PATENT ABSTRACTS OF JAPAN vol. 015, no. 181 (C - 0830) 9 May 1991 (1991-05-09) *
PATENT ABSTRACTS OF JAPAN vol. 1997, no. 10 31 October 1997 (1997-10-31) *
RUDOLPHI K. ET AL: "Propentofylline (HWA 285), a neuroprotective glial cell modulator: Pharmacologic profile.", CNS DRUG REVIEWS, (1997) 3/3 (260-277)., XP000863573 *

Also Published As

Publication number Publication date
WO2000007541A2 (de) 2000-02-17
AU5038499A (en) 2000-02-28

Similar Documents

Publication Publication Date Title
TR200000129T2 (tr) Yepyeni spiroazabisiklik heterosiklik bileşikler.
WO2002022598A8 (en) Quinolinone derivatives as tyrosine kinase inhibitors
WO2002034753A3 (en) Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
MY121294A (en) Novel hexanoic acid derivatives.
MY128659A (en) Novel aminodicarboxylic acid derivatives having pharmaceutical properties
AP9701019A0 (en) Phenylamino-substituted tricycle derivatives.
WO1998010767A3 (en) Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
WO1999064059A3 (en) Use of secretin for the treatment of autism and other neurological, behavioral and immunological disorders
NZ515392A (en) Respiratory syncytial virus replication inhibitors
WO2003051275A3 (en) Benzodiazepine derivatives, preparation thereof and use thereof
BG106681A (en) Solutions containing epinastine
BG103947A (en) Derivatives of 9-oxymerythromycin
FI940696A0 (fi) Uudet pyratsiinijohdannaiset, niiden valmistus ja käyttö
WO1997005870A3 (en) Use of griseofulvin for inhibiting the growth of cancers
EP1008344A4 (de) Neue verwendung von dikaffeoylchinasäure zur behandlung von hepatitis b und retroviraler krankenheiten, und die neuen kaffeoylchinasäurederivate
WO2001018004A3 (de) PYRAZOLO[4,3-d]PYRIMIDINE
WO2001081332A3 (en) 2-fluorobenzenesulfonyl compounds for the treatment of inflammation
GR3033350T3 (en) Use of Beta-aminopropionic acid derivatives as fungicides
DK0901790T3 (da) Anvendelse af moxonidin til behandling af neuropatisk smerte
AU2002220735A1 (en) Substituted derivatives of aminofuran-2-yl-acetic acid and aminothien-2-yl-acetic acid and the use thereof for treating migraines and pain
AU5727899A (en) Diaminocyclobutene-3,4-dione derivatives, their preparation and use
ATE225177T1 (de) Verwendung von (+)mefloquine zur behandlung von malaria
BR0012169A (pt) Dihidrobenzodiazepinas e seu uso no tratamento de dislipidemia
AU583375B2 (en) 2,4-diphenyl-1,3-dioxanes
WO2001060343A3 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und/oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA